Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 24% of new cases of B-cell non-Hodgkin lymphoma in the US each year. Up to 50% of patients relapse or are refractory (R/R) to the standard first-line treatment option, R-CHOP. The anti-CD19 monoclonal antibody tafasitamab, in combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Nedved, Adrienne, Maddocks, Kami, Nowakowski, Grzegorz S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Hematologic Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020798/
https://www.ncbi.nlm.nih.gov/pubmed/36648324
http://dx.doi.org/10.1093/oncolo/oyac256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020798/
https://www.ncbi.nlm.nih.gov/pubmed/36648324
http://dx.doi.org/10.1093/oncolo/oyac256

Ejemplares similares